Stony Brook Medicine, Mount Sinai Health team up

No "I" in "SBU:" Stony Brook Medicine will team up with NYC's vast Mount Sinai Health System to pursue new medical breakthroughs.

Academic synergies and accelerated discoveries are the promise of a new research collaboration pairing Stony Brook Medicine and the Mount Sinai Health System.

Stony Brook University and New York City-based Mount Sinai announced the new affiliation Thursday, with officials from both institutions highlighting the partnership’s superior research potential and innovative clinical-care initiatives.

Lab partner: The Icahn School and Stony Brook Medicine will share notes.

Lab partner: The Icahn School and Stony Brook Medicine will share notes.

Effective immediately, Stony Brook Medicine and the Icahn School of Medicine at Mount Sinai will begin developing new research programs – including medical-education and graduate-level programs – in fields including biomedical engineering, computer science, pharmaceutical discovery and public health, among others.

Stony Brook University President Samuel Stanley Jr. called it “a momentous day for academic medicine, healthcare, our respective students, faculty and staff, and for all those who are cared for by our teams of highly trained, dedicated clinicians.”

Icahn School of Medicine at Mount Sinai Dean Dennis Charney said the partnership would “revolutionize medical research.”

“Both institutions are committed to a culture of innovation in research and education,” noted Charney, who doubles as president of academic affairs for the Mount Sinai system. “We look forward to working with Stony Brook to help make exciting breakthroughs in healthcare.”

Encompassing the Icahn School of Medicine at Mount Sinai and seven hospital campuses, the Mount Sinai Health System boasts 5,000 faculty members and more than 2,000 students, residents and fellows, most centered at the Icahn School of Medicine.

Chartered in 1963, the only school in the Mount Sinai chain operates 14 distinct research institutes, with focus areas ranging from stem cells and metabolic disease to drug discovery and global health.

Through Mount Sinai’s collaboration with SBU, students from both systems will have the opportunity to attend cross-curriculum classes on both campuses, exposing them to tools and techniques unique to the partner institution.

Stony Brook Medicine and Mount Sinai also plan to create new extracurricular summer programs on the undergraduate, graduate and postgraduate levels, while simultaneously investing a combined $500,000 to create and launch “unique pilot programs” aimed at attracting external funding for new research initiatives, according to SBU.

Eric Nestler, dean for academic and scientific affairs and director of the Freidman Brain Institute at the Icahn School of Medicine at Mount Sinai, called it “a major investment that will have a dramatic influence on both campuses’ ability to advance education, research, diagnostics and treatment.”

Dubbing the SBU and Mount Sinai systems “powerhouses of research,” Lina Obeid, dean of research and vice dean of scientific affairs at Stony Brook Medicine, agreed the two combined institutions can “yield greater discoveries than just the sum of their parts.”

“Major breakthroughs in improving diagnostics and therapeutics in healthcare come from research, usually starting at the very basic level,” Obeid said in a statement. “The joint pilots in research have immense promise to advance health at the most exciting time in the biomedical sciences, including advanced computational, bioinformatic and engineering approaches.”